arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

MIRA PHARMACEUTICALS, INC.

MIRA

$0.75 ▲ +0.07 (+9.59%) at close

13 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

MIRA PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $12.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC None

FCF / Share None

Trailing P/E —

Price / Book 14.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-1.78M

↓ -3.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Dec 31, 2023 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Dec 31, 2022 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	26.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-1550.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	46.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-10.0% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-50.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	85.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-85.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	47.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-3.8% Weak ↑ Weak Improving Year-over-year change in net income	-201.0% Weak ↓ Weak Declining Year-over-year change in net income	52.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-35.7% Weak ↓ Weak Declining Year-over-year change in net income	-28.1% Weak ↓ Weak Declining Year-over-year change in net income	73.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-143.2% Weak Weak Year-over-year change in net income	14.2% Fair Fair Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

💰 Are margins durable? 2 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Dec 31, 2023 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Dec 31, 2022 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF Margin (%) (%) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FCF / Net Income (x) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Dec 31, 2023 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Dec 31, 2022 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Capital (%) (%)	-16.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-45.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-58.8% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-58.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-58.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-72.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-127.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-171.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-171.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-81.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-641%)	-48.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-420%)	-39.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-362%)	-39.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-362%)	-39.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-362%)	-75.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-602%)	-82.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-647%)	-28.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-293%)	-30.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-304%)	-143.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1056%)	247.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1549%)	247.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1549%)	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Dec 31, 2023 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Dec 31, 2022 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Interest Coverage (x) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Debt (USD) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt / EBITDA (x) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Dec 31, 2023 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Dec 31, 2022 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-0.11	$-0.99	$-0.14	$-0.11	$-0.15	$-0.06	$-0.26	$-0.10	$-0.10	$-0.42	$-0.14	$-0.19	—
Free Cash Flow per Share (USD) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Book Value per Share (USD)	$0.05	$0.25	$0.26	$0.26	$0.26	$0.13	$0.30	$0.30	$0.30	$0.30	$-0.04	$-0.04	$-0.04
Tangible Book Value per Share (USD)	$0.05	$0.25	$0.26	$0.26	$0.26	$0.13	$0.30	$0.30	$0.30	$0.30	$-0.04	$-0.04	$-0.04
Basic Weighted Avg Shares (shares)	16.65M	—	15.07M	14.78M	14.78M	—	13.64M	13.31M	17.75M	—	13.17M	13.09M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Dec 31, 2023 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Dec 31, 2022 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD) N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity (USD)	$2.20M	$10.39M	$4.37M	$4.37M	$4.37M	$2.20M	$4.37M	$4.37M	$4.37M	$4.37M	$-596.23K	$-596.23K	$-596.23K

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Dec 31, 2023 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Dec 31, 2022 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Income, GAAP (USD)	$-1.78M	$-4.99M	$-1.72M	$-1.72M	$-1.72M	$-1.66M	$-3.59M	$-1.27M	$-1.34M	$-6.27M	$-1.48M	$-1.48M	—
Operating Cash Flow (USD)	$-1.63M	$-906.09K	$-1.84M	$-863.93K	$-1.05M	$-2.06M	$-1.76M	$-660.81K	$-1.08M	$96.92K	$-1.31M	—	—

🏛️ Sector-Specific 1 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Dec 31, 2023 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Dec 31, 2022 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Interest Margin (approx.) (%)	0.8%	-1.0%	5.2%	—	—	—	—	—	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 13 quarters

MIRA PHARMACEUTICALS, INC.

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MIRA with peers